Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that its controlling subsidiary, Zhejiang Jiuzhou Biomedical Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Oxcarbazepine Tablets issued by the National Medical Products Administration. Oxcarbazepine tablets are used to treat primary generalized tonic-clonic seizures and partial seizures with or without secondary generalized seizures.
九洲药业(603456.SH)：奥卡西平片获得药品注册证书
Zhejiang Jiuzhou Pharmaceutical (603456.SH): Okasipin tablets obtained pharmaceutical registration certificate.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.